The study found that the CBIRF's expanded mission encompassed the full scope of chemical, biological, radiological, nuclear, and explosive attacks, all of which have been or are projected to be methods of terrorist attacks. The analysis found weaknesses in medications for biological and radiological events, crush syndrome, and medical conditions that might be encountered in extreme environmental conditions. It made detailed calculations for trauma supplies required for 100 patients with some 400 injuries and illnesses. The study identified new technologies and products that enhanced CBIRF's medical capabilities while remaining within unit weight and volume restrictions. Calculations for biochemical medications were based on dosage information developed to determine the required amount of medications for the Marine Corps Surgical Company's nuclear, biological, and chemical warfare supply block. A list of recommended medications for radioactive agents was developed, along with antacids and laxatives that can help prevent absorption and assist the elimination of radioactive elements from the body. Since CBIRF's expanded mission could involve work in extreme climates throughout the world, separate supply inventories were prepared for hot and cold weather. The study was conducted by the Naval Health Research Center (NHRC), which reviewed CBIRF Authorized Medical Allowance Lists (AMALs) to determine whether they were adequate for the expanded mission. Recommendations were submitted for review by a SME panel that convened November 18-20, 2003. The panel consisted of 15 military and civilian experts in military medicine, medical logistics, and the treatment of victims of weapons of mass destruction. 5 tables and 8 references